A Retrospective Subgroup Analysis of EGFR Immunohistochemistry (IHC) Expression by Histo-Score Correlated to Outcomes From the BMS099 1st Line Phase III NSCLC Trial of Cetuximab (Cet) Plus Carboplatin/Taxane

被引：5

作者：

Lynch, T. ^{[1
]}

Bhagavatheeswaran, P. ^{[2
]}

Mukhopadhyay, P. ^{[2
]}

Khambata-Ford, S. ^{[3
]}

Harbison, C. T. ^{[3
]}

机构：

[1] Yale Univ, Sch Med, Smilow Canc Hosp Yale New Haven, New Haven, CT USA

[2] Bristol Myers Squibb Co, Global Biometr Sci, Wallingford, CT 06492 USA

[3] Bristol Myers Squibb Co, Clin Biomarkers, Wallingford, CT 06492 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(11)72313-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S591 / S592

页数：2